Rahul Sharma (Editor)

Circassia Pharmaceuticals

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Type  Public limited company
Industry  Pharmaceuticals
Operating income  £(66.4) million (2015)
Headquarters  United Kingdom
Chief business officer  David Hipkiss
Traded as  LSE: CIR
Founded  2006
CEO  Steve Harris
Revenue  10.8 million GBP (2015)
Circassia Pharmaceuticals httpsrescloudinarycomcrunchbaseproductioni
Key people  Francesco Granata, (Chairman) Steven Harris, (CEO)
Stock price  CIR (LON) 86.19 GBX +1.19 (+1.40%)3 Mar, 5:01 PM GMT - Disclaimer

Circassia pharmaceuticals


Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.

Contents

Circassia pharmaceuticals


History

The company was founded by Steve Harris and Charles Swingland in 2006. It was the subject of an Initial Public Offering in March 2014.

Operations

The company's technology, ToleroMune, was initially developed by scientists at Imperial College London. The company is in the process of developing a treatment for cat allergies.

References

Circassia Pharmaceuticals Wikipedia


Topics
 
B
i
Link
H2
L